Ibn Al-Haytham Pharmaceutical Industries is a leading pharmaceutical manufacturing company established in 1992 in Aleppo, Syria. The company has expanded its operations to include facilities in Lattakia and focuses on the development, manufacturing, and marketing of a wide range of generic pharmaceutical products, aiming to provide innovative and high-quality medicines to the Syrian and global markets.
The company positions itself as a 'Partner in Health,' emphasizing quality, efficacy, and safety in its manufacturing processes. It maintains an active presence in the medical community through clinical studies, post-marketing research, and educational workshops for healthcare professionals, covering various therapeutic areas including cardiology, pediatrics, and chronic disease management.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Founded:1992
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Syrian Cardiovascular Association (collaboration on cardiology conferences and research)
COMPETITION
Position:Niche Player
LINKS
Website:ibn-alhaytham.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Ibn Al-Haytham Pharmaceutical Industries and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ibn Al-Haytham Pharmaceutical Industries. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.